Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters

Author(s):
Bresters, D.; Lawitschka, A.; Cugno, C.; Potschger, U.; Dalissier, A.; Michel, G.; Vettenranta, K.; Sundin, M.; Al-Seraihy, A.; Faraci, M.; Sedlacek, P.; Versluys, A.B.; Jenkins, A.; Lutz, P.; Gibson, B.; Leiper, A.; Diaz, M.A.; Shaw, P.J.; Skinner, R.; O'Brien, T.A.; Salooja, N.; Bader, P.; Peters, C.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-11-30
Language
English
Is part of
Bone Marrow Transplantation (2016), Vol. 51, no. 11, p. 1482-1489
hdl
1887/111999
doi
10.1038/bmt.2016.139